Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative ‘GLP-1 Obesity Treatment’ with Advanced Microneedle Technology for Sustained Weekly Efficacy

The ultra-small 1cm² patch, which only needs to be applied once a week, dramatically increases user convenience Daewoong Therapeutics employs the ‘CLOPAM’ platform to develop ‘advanced formulations,’ with plans for commercialization by 2028 CEO Seung-Ho Jeon states, “By developing the…